Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
REP 2139-Mg
DRUG
2 trials
Sponsors
Replicor Inc.
Conditions
Ascites Hepatic
Chronic Hepatitis B
Cirrhosis, Liver
Decompensated Cirrhosis
Hepatocellular Carcinoma
Varices, Esophageal
Viral Hepatitis B
Viral Hepatitis D
Phase 2
REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection
Completed
NCT02565719
Replicor Inc.
Chronic Hepatitis B
Start: 2016-03-31
End: 2019-05-31
Updated: 2019-09-10
Unknown Phase
Replicor Compassionate Access Program
NCT05683548
Replicor Inc.
Ascites Hepatic, Cirrhosis, Liver, Decompensated Cirrhosis +4
Updated: 2025-02-17
Related Papers
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.
2025-11-06
1 citations
Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
Hepatology Communications
2023-07-17
13 citations
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy
Hepatology Communications
2021-07-10
20 citations
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy
Journal of Viral Hepatitis
2021-02-09
15 citations
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
Gastroenterology
2020-03-05
218 citations
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
PLoS ONE
2016-06-03
176 citations